Artelo Biosciences Inc ARTL
π Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-10-13 |
| Shares Out. | 3,490,000 |
| Website | artelobio.com/ β |
| Phone | 18589257049 |
| Employees | 7 |
| Net Income | -$3.0M |
| Free Cash Flow | -$8.4M |
| Total Assets | $12.5M |
| Total Liabilities | $5.8M |
| Equity | $6.7M |
About Artelo Biosciences Inc
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Artelo Biosciences Inc is a publicly traded company under the ticker symbol ARTL on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
π Analyst Ratings
6 analysts (2026-07-01)

